LFCR

Handel nachbörslich: 4.65 -0.07 -1.48%

Lifecore Biomedical Inc (LFCR)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Lifecore Biomedical Inc Stock (LFCR) Company Profile

Lifecore Biomedical Inc

Healthcare (1080)

(952) 368-4300

3515 LYMAN BOULEVARD, CHASKA

Nächster Verdiensttermin

Neueste SEC-Einreichungen

LFCR's Discussions on Twitter

Compare LFCR vs TAK, TEVA, HLN, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
LFCR Lifecore Biomedical Inc	4.72	180.56M	147.12M	-33.88M	-13.62M	-0.4805
TAK Takeda Pharmaceutical Co Adr	17.63	55.60B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.77	42.81B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.70	43.16B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	73.79	30.39B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	499.73	21.95B	3.17B	1.29B	1.01B	27.09

Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-17	Hochstufung	Barrington Research	Mkt Perform → Outperform
2025-09-04	Eingeleitet	KeyBanc Capital Markets	Sector Weight
2025-05-21	Eingeleitet	William Blair	Outperform
2024-09-05	Eingeleitet	Craig Hallum	Buy
2024-08-28	Herabstufung	Barrington Research	Outperform → Mkt Perform
2023-03-20	Herabstufung	Stephens	Overweight → Equal-Weight

Alle ansehen

Lifecore Biomedical Inc Aktie (LFCR) Neueste Nachrichten

Finanzdaten der Lifecore Biomedical Inc-Aktie (LFCR)

Lifecore Biomedical Inc (LFCR)

Lifecore Biomedical Inc Stock (LFCR) Company Profile

Compare LFCR vs TAK, TEVA, HLN, ZTS, UTHR

Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades

Lifecore Biomedical Inc Aktie (LFCR) Neueste Nachrichten

Avoiding Lag: Real-Time Signals in (LFCR) Movement - Stock Traders Daily

Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript - AOL.com

Judge approves $3.75 million Lifecore investor settlement - Minnesota Lawyer

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update - marketscreener.com

Lifecore Biomedical, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Discipline and Rules-Based Execution in LFCR Response - news.stocktradersdaily.com

Earnings call transcript: Lifecore Biomedical tops revenue view in Q2 2026 - Investing.com Canada

Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat

Transcript : Lifecore Biomedical, Inc., Q2 2026 Earnings Call, Aug 05, 2026 - marketscreener.com

Lifecore Biomedical, Inc. Reaffirms Earnings Guidance for the Calendar Year 2026 - marketscreener.com

Lifecore Biomedical, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Lifecore Biomedical Q2 Earnings Call Highlights - marketbeat.com

Lifecore Biomedical, Inc. (LFCR) Q2 FY2026 earnings call transcript - Yahoo Finance

LFCR: Q2 revenue fell 6.2% to $34.2M, but new business wins and guidance reaffirmed - TradingView

Lifecore Biomedical Backs 2026 Adj EBITDA of $20.5M-$25M >LFCR - Moomoo

Lifecore Biomedical Q2 revenue falls to $34.2 million as loss widens - Quiver Quantitative

Lifecore Biomedical 2026: Revenue $34.17M, EPS ($0.19) — 10-Q Summary - TradingView

Lifecore Biomedical: Q2 Earnings Snapshot - marketscreener.com

Lifecore Biomedical (NASDAQ: LFCR) Q2 revenue slips as 2026 guidance reaffirmed - Stock Titan

Press Release: Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update - moomoo.com

LFCR: Q2 2026 delivered strong revenue, margin expansion, and robust pipeline growth - TradingView

Lifecore Biomedical Q2 FY26 net loss widens to $6.2 million; revenue falls 6.2% to $34.2 million - Bitget

Lifecore Biomedical Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile

Zacks Research Upgrades Lifecore Biomedical (NASDAQ:LFCR) to Hold - marketbeat.com

Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026 - GlobeNewswire

Lifecore Sets Aug. 5 Webcast for Second-Quarter Results - Stock Titan

Lifecore Biomedical (LFCR) Tests Resistance After a Modest UptickBull Flag - dars.gov.et

Lifecore Biomedical signs three new customer de... - Pluang

Lifecore Biomedical Signs Three New Customer Agreements - The Manila Times

Lifecore Biomedical Announces Three New Customer Agreements Spanning Late-Stage Regenerative Medicine and Early-Stage Development Programs - Quiver Quantitative

Regenerative Medicine and Device Programs Expand Lifecore’s Pipeline - Stock Titan

Lifecore Biomedical Inc (LFCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Lifecore Biomedical Inc (LFCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Lifecore Biomedical Inc (LFCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

LFCR|Lifecore Biomedical Inc|Price:4.330|Chg%:-0.100 - TradingKey

Lifecore Biomedical Inc (LFCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Lifecore Biomedical (LFCR) Slips 2.26% as Stock Tests Key Support Near $4.11Defined Outcome ETF - dars.gov.et

Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical - The National Law Review

Lifecore Biomedical, Inc. Revenue Breakdown – NASDAQ:LFCR - TradingView

Lifecore Biomedical (LFCR) Pulls Back: Testing Key Support After 2.26% DeclineNegative Gamma - dars.gov.et

Lifecore Biomedical Inc. (LFCR) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin Amid Operational ChallengesBook Value Growth - dars.gov.et

LFCR|Lifecore Biomedical Inc|Price:4.340|Chg%:+0.010 - TradingKey

Lifecore Biomedical (LFCR) Q1 2026 earnings summary - Quartr

Lifecore Biomedical (LFCR) Proxy filing Summary - Quartr

LFCR Deadline: LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit - GuruFocus

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm

What Triggered Lifecore Biomedical's Recent Stock Plunge - Kavout | AI

New Lifecore Hire Gets 3,500 Stock Units Vesting in Three Years - Stock Titan

Finanzdaten der Lifecore Biomedical Inc-Aktie (LFCR)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie LFCR